•  

Media Coverage

TIAP and Evotec Expand LAB150 Bridge Partnership to Include Amgen

TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb LAB150 was created in 2017 with Evotec as the first North American BRIDGEs program to accelerate the development of novel therapeutics from our Members. Today’s announcement not only provides pre-seed capital of US$14M to these emerging drug development projects but also significant expertise and mentorship to our local scientists and innovators from ... Read more

LAB150 launches new immuno-oncology project from Sunnybrook Research Institute

Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his lab at Sunnybrook Research Institute, a TIAP Member institution. The last several years has seen the introduction of a new blockbuster class of drugs for treating cancers – specifically, the immune checkpoint inhibitors (ICIs). These drugs act ... Read more

TIAP Announces New President and CEO

Toronto, Ontario, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of TIAP – Toronto Innovation Acceleration Partners (formerly MaRS Innovation) – is pleased to announce the appointment of Parimal Nathwani as TIAP’s new President and Chief Executive Officer effective April 1, 2020.  Nathwani succeeds Dr. Raphael Hofstein who has served as the organization’s leader since 2009. Parimal Nathwani, who currently serves as TIAP’s Vice President, has been with the organization since its inception in 2009 and has been fundamental to ... Read more

Allogene Therapeutics enters collaboration with Notch Therapeutics

Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales SOUTH SAN FRANCISCO, Calif. and TORONTO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic ... Read more

Amgen Deal in Re$earch Money

In their September 11, 2019 online edition as part of their "Innovation this Week" newsletter, Re$earch Money talked about TIAP's partnership agreement with Amgen: "A few days after celebrating its 10th anniversary and changing its name to Toronto Innovation Acceleration Partners (TIAP), the commercialization organization formerly known as MaRS Innovation announced a new collaboration with the biotechnology company Amgen. The aim of the collaboration is to identify and jointly fund disruptive technologies derived from discovery research conducted in Toronto and managed by ... Read more

BetaKit Article on Amgen Partnership

Jessica Galang of BetaKit, a Canadian online publication on start-up news and tech innovation, writes about TIAP's recently announced strategic partnership with Amgen.  Read more here: http://bit.ly/2lSDVYE   Read more

LAB150 adds two projects: Cystic Fibrosis and Respiratory Syncytial Virus

Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. LAB150 is a partnership between MaRS Innovation and Evotec AG with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms ... Read more

Fibrocor Therapeutics enters deal with Galapagos NV

Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs. In 2017 MaRS Innovation founded, and subsequently seed-funded, Fibrocor. The company is based on research from two of MaRS Innovation’s Member institutions, St. Michael’s Hospital and Sinai Health Systems – specifically, from the labs of Drs. Richard ... Read more

IP Protection for Antibody-based Assets in the Canadian Market and beyond

Together with Noel Courage, MI's Philip Goldbach co-authored an article published in BioTechnology Focus on IP rights and considerations surrounding antibody-based assets.  As the article states: Antibodies (immunoglobulins) and other antibody-derived biologics have become a mainstay of the biotechnology industry, both here in Canada and around the world. Novel antibodies are continuously being designed, modified, expressed and purified for a number of uses, including as therapeutics, diagnostics, or research tools. As is the case with other types of life science technologies, intellectual ... Read more

LAB150 – A new paradigm in drug discovery

Click on link to read an article by Drs. Rafi Hofstein and Werner Lanthaler published in December 2017 in the online publication Global University Venturing: http://bit.ly/2Ba9vH2 Read more
Page 1 of 2012345...1020...Last »